146 related articles for article (PubMed ID: 30856039)
21. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Cancer; 2010 May; 116(9):2224-33. PubMed ID: 20209608
[TBL] [Abstract][Full Text] [Related]
24. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
Jensen HK; Donskov F; Nordsmark M; Marcussen N; von der Maase H
Clin Cancer Res; 2009 Feb; 15(3):1052-8. PubMed ID: 19188179
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.
Serag El-Dien MM; Abdou AG; Asaad NY; Abd El-Wahed MM; Kora MAEM
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):534-542. PubMed ID: 26862953
[TBL] [Abstract][Full Text] [Related]
26. The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers.
Sun DS; Zhao MQ; Xia M; Li L; Jiang YH
Med Oncol; 2012 Jun; 29(2):707-13. PubMed ID: 21424865
[TBL] [Abstract][Full Text] [Related]
27. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
29. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
30. IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.
Cui G; Li Z; Ren J; Yuan A
Virchows Arch; 2019 Nov; 475(5):579-586. PubMed ID: 31062086
[TBL] [Abstract][Full Text] [Related]
31. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection.
Wang B; Xu D; Yu X; Ding T; Rao H; Zhan Y; Zheng L; Li L
Ann Surg Oncol; 2011 Sep; 18(9):2585-93. PubMed ID: 21347781
[TBL] [Abstract][Full Text] [Related]
32. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.
Lee NR; Song EK; Jang KY; Choi HN; Moon WS; Kwon K; Lee JH; Yim CY; Kwak JY
Leuk Lymphoma; 2008 Feb; 49(2):247-56. PubMed ID: 18231910
[TBL] [Abstract][Full Text] [Related]
35. Increased CD200 expression in post-transplant lymphoproliferative disorders correlates with an increased frequency of FoxP3(+) regulatory T cells.
Vaughan JW; Shi M; Horna P; Olteanu H
Ann Diagn Pathol; 2020 Oct; 48():151585. PubMed ID: 32829067
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
37. Critical stoichiometric ratio of CD4(+) CD25(+) FoxP3(+) regulatory T cells and CD4(+) CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.
Bhattacharya K; Chandra S; Mandal C
Immunology; 2014 May; 142(1):124-39. PubMed ID: 24354800
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
39. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
[TBL] [Abstract][Full Text] [Related]
40. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Giatromanolaki A; Bates GJ; Koukourakis MI; Sivridis E; Gatter KC; Harris AL; Banham AH
Gynecol Oncol; 2008 Aug; 110(2):216-21. PubMed ID: 18533240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
